Clinique Pasteur Lanroze — Clinical Trial Site

36 Registered trials

18 Currently recruiting

Organisation

Clinique Pasteur Lanroze

Location

Brest, France

Identifier

ORG-100045599

Address

32 Rue Auguste Kervern, 29200, France

Departments

CFRO -Clinique Pasteur
Clinique Pasteur
Medical Oncology
Oncologie
Oncologie médicale
Oncologie Radiothérapie
Oncology
Oncology / Radiotheray
oncology department
Oncology-Radiotherapy
Radiation-oncologist
Radiology/Oncology
Radiothérapie
Radiotherapy
Radiotherapy Oncology
Service d'Oncologie médicale
Service Oncologie-Radiothérapie

Clinical trials at this site (36)

Search interface

An open study for participants who have been on darolutamide treatment in any other Bayer study Ended

2022-502084-38-00 Cancer 5 2020-10-16
CREST - Phase 3 Study of Sasanlimab (PF-06801591) in Combination With Bacillus Calmette-Guerin (BCG) or as a Single Agent in Participants Wi… Ended

2023-509089-39-00 Non-Muscle Invasive Bladder Cancer 5 2020-07-01
A clinical study evaluating the benefits of apalutamide, a novel drug targeting prostate cancer growth, in combination with radiotherapy and… Ended

2024-514829-36-00 High-risk biochemically-relapsed prostate adenocarcinom 5 2019-12-02
Prostate cancer with OligometaSTatic relapse: Combining stereotactic Ablative Radiotherapy and Durvalumab (MEDI4736), a randomized phase II … Ended

2024-513207-13-00 oligometastatic hormone sensitive prostate cancer 4 2019-03-21
Randomized trial evaluating the addition of nivolumab to cisplatin-radiotherapy combination for treatment of cancers of the head and neck Ended

2024-513206-65-00 resected squamous cell carcinoma of head and neck 5 2018-08-10
Randomized trial of avelumab-cetuximab-Radiotherapy versus standards of care in the head and neck cancers Ended

2024-513964-24-00 Squamous cell carcinoma, previously untreated Stage III 5 2017-09-14
PAlbociclib and Circulating Tumor DNA for ESR1 Mutation Detection Ended

2024-510704-37-00 ER+/HER2- metastatic breast cancer 5 2017-03-22
An international study to evaluate the safety and effectiveness of enzalutamide plus leuprolide, enzalutamide alone, and leuprolide alone in… Ended

2024-513521-23-00 Prostate Cancer 5 2015-08-19
PRODIGE 34 - ADAGE: Randomised phase III study evaluating adjuvant chemotherapy after resection of stage III colon adenocarcinoma in patient… Ended

2024-518741-21-00 colon cancer 4 2014-12-23
A large-scale comparative study evaluating an intravenous treatment, cabazitaxel, and radiation therapy to the pelvic lymph nodes in patient… Ended

2024-517622-25-00 Patients with localized prostate cancer and high-risk f 5 2013-12-06
Detection of tumor DNA in the blood of patients receiving standard therapy for hormone receptorpositive (HR+) non-HER2 expressing (HER2-) me… Ended

2022-502372-22-01 Metastatic Breast Cancer HR+, HER2- 4 2023-10-19
PRODIGE 76-IMMUNOBILADJ: Capecitabine plus durvalumab or capecitabine alone as adjuvant therapy in patients with resected biliary tract carc… Ended

2023-503807-27-00 Biliary tract carcinoma 4